Cargando…
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early inflammatory demyelination and subsequent neurodegeneration. Major therapeutic progress has occurred during the past decade, in particular since the introduction of immunomodulatory agents...
Autores principales: | Thöne, Jan, Ellrichmann, Gisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585507/ https://www.ncbi.nlm.nih.gov/pubmed/23459383 http://dx.doi.org/10.2147/DHPS.S28822 |
Ejemplares similares
-
An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019) -
Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017) -
Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
por: Paul, Friedemann, et al.
Publicado: (2008) -
Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022) -
Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia
por: Alsaqa’aby, Mai F., et al.
Publicado: (2017)